Ação Affimed (AFMD)
Empresa do setor de saúde. Aqui estão o preço, um resumo do negócio e o que vale a pena saber sobre Affimed em junho 2026.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Resumo do desempenho da ação
Avaliação dos analistas
Analysts recommend buying AFFIMED NV stock, expecting significant growth potential towards the target price.
Saúde financeira
Affimed NV has low revenue and book value per share, indicating potential financial challenges.
Veja mais ações baixando o app GRÁTIS
Leva só 60 segundos.
Descubra mais oportunidades
ACADIA PHARMACEUTICALS INC
Desenvolve e comercializa medicamentos para transtornos do sistema nervoso central.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
Desenvolve tecnologias para descobrir anticorpos monoclonais a partir de sistemas imunes naturais para uso em fármacos terapêuticos.
Cestas que incluem AFMD
Ações alemãs em ascensão
Desfrute de uma coleção cuidadosamente selecionada de empresas alemãs que vêm superando dramaticamente seus pares ocidentais. Nossa equipe de analistas profissionais identificou essas ações de destaque à medida que a economia da Alemanha mostra sinais promissores de crescimento em 2025.
Publicado: 15 de maio de 2025
Explorar cestaPor que investir com a Nemo?
Zero comissão
Negocie ações, ETFs e muito mais sem comissão. Fique com uma parte maior dos seus retornos.
Confiável e regulamentado
Parte do grupo Exinity desde 2015, atendendo a mais de um milhão de clientes em todo o mundo.
6% de juros sobre o saldo
Ganhe 6% AER sobre o dinheiro não investido, com pagamentos de juros diários.